Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | STS | P08842 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | HTR1D | P28221 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 3/20 | 0.35 |
| ▸ | CHEK2 | O96017 | 4/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30387165 | 1.00 | TSHR (0.53) | TSHRSTSHTR1AHTR1DHTR2C | |
| SCHEMBL6649922 | 0.87 | STS (0.54) | TSHRSTSHTR1AHTR1DHTR2C | |
| SCHEMBL30027075 | 0.85 | ALDH1A1 (0.51) | TSHRSTSCYP2B6NPC1RAB9A | |
| SCHEMBL876479 | 0.85 | ALDH1A1 (0.51) | TSHRSTSCYP2B6NPC1RAB9A | |
| SCHEMBL19691119 | 0.81 | CYP2B6 (0.39) | TSHRSTSCYP2B6NPC1RAB9A | |
| SCHEMBL27918004 | 0.80 | CA12 (0.49) | TSHRNPC1RAB9ACASP3SMN1; SMN2 | |
| SCHEMBL27917978 | 0.76 | GABRA1 (0.39) | STSCYP2B6NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5917802 | 0.76 | CA12 (0.48) | TSHRNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL15638307 | 0.75 | TSHR (0.60) | TSHRHTR1AHTR1DHTR2CNPC1 | |
| SCHEMBL25206719 | 0.75 | NPC1 (0.60) | NPC1RAB9ACASP3SMN1; SMN2SENP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023090822-A1 | NOVEL CANNABICHROMENIC ACID DERIVATIVE, PREPARATION METHOD THEREFOR, AND COMPOSITION COMPRISING SAME FOR IMPROVING COGNITIVE FUNCTION | 강원대학교 산학협력단 | 2023-05-25 | — | — | WO | claimed |
| CN-120035587-A | Novel indazole derivative or pharmaceutically acceptable salt thereof and use thereof | 高丽大学校产学协力团 | 2025-05-23 | — | — | CN | disclosed |
| US-20250092008-A1 | PROCESS FOR MAKING AN EP4 ANTAGONIST | ONO PHARMACEUTICAL CO., LTD. (JP) | 2025-03-20 | — | — | US | disclosed |
| WO-2024080780-A1 | NOVEL INDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF | 고려대학교 산학협력단 | 2024-04-18 | — | — | WO | disclosed |
| CN-117615763-A | Phosphoinositide 3 kinase beta inhibitor, composition and preparation method thereof | 健道生物医药有限公司 | 2024-02-27 | — | — | CN | disclosed |
| WO-2023090822-A1 | NOVEL CANNABICHROMENIC ACID DERIVATIVE, PREPARATION METHOD THEREFOR, AND COMPOSITION COMPRISING SAME FOR IMPROVING COGNITIVE FUNCTION | 강원대학교 산학협력단 | 2023-05-25 | — | — | WO | disclosed |
| CN-105142629-B | It is treated in combination | 阿斯利康(瑞典)有限公司 | 2018-11-23 | — | — | CN | disclosed |
| CN-105142629-B | It is treated in combination | 阿斯利康(瑞典)有限公司 | 2018-11-23 | — | — | CN | disclosed |
| CN-104447657-B | There is the chromene ketone derivatives of anti-tumor activity | 阿斯利康(瑞典)有限公司 | 2016-08-17 | — | — | CN | disclosed |
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| EP-2493870-A1 | CHROMENONE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | AstraZeneca AB (SE) | 2012-09-05 | — | — | EP | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
| WO-2011051704-A1 | CHROMENONE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | ASTRAZENECA AB (SE) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250092008-A1 | PROCESS FOR MAKING AN EP4 ANTAGONIST | PTGER4, LTB4R2, EPB41 | TSHR 1750/4885STS 3729/4885HTR1A 240/4885 |
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | TSHR 586/4885STS 4238/4885HTR1A 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.